IQVIA continues to focus on improving efficiencies for sites and
study teams with its latest cross-trial updates
DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
IQVIA™ (NYSE:IQV) today launched two new capabilities to support
clinical teams more easily and quickly share cross-trial training
materials and safety notifications. These features were co-designed,
tested, and are now in use by two of the top-five pharmaceutical
companies.
IQVIA Technologies’ cross-trial functionality helps simplify the work of
study teams by allowing sponsors and contract research organizations to
push training materials and safety notifications to sites across
multiple studies, geographic locations, and site roles in just a few
clicks. Both systems are administered through a streamlined dashboard
that allows users to easily push and track trainings and safety
notifications. These upgrades reduce site workload by ensuring the
required clinical trainings and safety notifications are distributed and
tracked across all trials, removing redundancies in training or safety
acknowledgement. These capability enhancements are now available for use
on all IQVIA full-service clinical studies.
“Our latest platform upgrades help ensure that sponsors, IQVIA, and
other CROs can notify sites about safety events and trainings from one
centralized dashboard, while removing duplicative activities that were
previously inherent in the process. Simply put, this makes it easier for
everyone,” said Tal Rosenberg, senior vice president, Global Technology
Solutions at IQVIA.
Features and benefits include:
-
Simple dissemination, receipt, acknowledgement, and tracking of safety
notifications and training.
-
Reduced workload for sites and study teams.
-
Transparency in audit-trail documentation through automatic tracking
of notification, acknowledgement.
-
Cost and time savings.
-
Decreased audit and legal liability.
-
Automatic identification of noncompliant site personnel for training
and safety acknowledgement.
IQVIA Technologies’ commitment is to support better decision-making
through new technologies that extract deep insights using robust
clinical data, advanced analytics, and healthcare expertise.
Additional information about the site portal is available at http://www.drugdev.com/iqvia-lms/
and http://www.drugdev.com/iqvia-safety-notifications/.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics,
technology solutions and contract research services to the life sciences
industry. Formed through the merger of IMS Health and Quintiles, IQVIA
applies human data science — leveraging the analytic rigor and clarity
of data science to the ever-expanding scope of human science — to enable
companies to reimagine and develop new approaches to clinical
development and commercialization, speed innovation and accelerate
improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA
delivers unique and actionable insights at the intersection of
large-scale analytics, transformative technology and extensive domain
expertise, as well as execution capabilities. With more than 58,000
employees, IQVIA conducts operations in more than 100 countries.
IQVIA is a global leader in protecting individual patient privacy. The
company uses a wide variety of privacy-enhancing technologies and
safeguards to protect individual privacy while generating and analyzing
information on a scale that helps healthcare stakeholders identify
disease patterns and correlate with the precise treatment path and
therapy needed for better outcomes. IQVIA’s insights and execution
capabilities help biotech, medical device and pharmaceutical companies,
medical researchers, government agencies, payers and other healthcare
stakeholders tap into a deeper understanding of diseases, human
behaviors and scientific advances, in an effort to advance their path
toward cures. To learn more, visit www.iqvia.com.
Click
here to subscribe to Mobile Alerts for IQVIA.
IQVIAFIN
View source version on businesswire.com:
https://www.businesswire.com/news/home/20190131005273/en/
Tor Constantino, IQVIA Media Relations (tor.constantino@iqvia.com)
+1.484.567.6732
Andrew Markwick, IQVIA Investor Relations (andrew.markwick@iqvia.com)
+1.973.257.7144
Source: IQVIA